|drug1080||Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation Wiki||1.00|
|drug1078||Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation Wiki||1.00|
|drug1081||Standard therapy recommended by the Ministry of Health of the Russian Federation. Wiki||1.00|
|D011665||Pulmonary Valve Insufficiency NIH||0.50|
|D012141||Respiratory Tract Infections NIH||0.23|
There is one clinical trial.
The purpose of the study is to evaluate an effectiveness of the drug Dalargin for the prevention and treatment of severe pulmonary complications symptoms associated with severe and critical coronavirus infection cases (SARS COVID19, expanded as Severe acute respiratory syndrome Cоrona Virus Disease 2019 ). Test drug that will be administered to patients are: - Dalargin, solution for inhalation administration, - Dalargin, solution for intravenous and intramuscular administration.
Description: Estimated by Polymerase chain reaction (PCR)Measure: The change of viral load in patients with SARS-COVID-19. Time: Upon patient inclusion in the study, after 96 hours and on the 10day;
Description: Assessed through the entire patient participation in the studyMeasure: The frequency of development of Acute Respiratory Distress Syndrome (ADRS) Time: up to 8 months
Description: The number of days a patient is hospitalizedMeasure: Duration of hospitalization Time: through study completion, an average of 8 months
Description: Early mortality from all causes will be estimatedMeasure: The frequency of early mortality Time: up to 30 days
Description: Late mortality from all causes will be estimatedMeasure: The frequency of late mortality Time: up to 90 days
Description: Clinical status at the time of completion of participation in the study will be estimated based upon the following criteria: Death; Hospitalization is extended, on invasive mechanical ventilation of the lungs with extracorporeal membrane oxygenation; Hospitalization extended, on non-invasive ventilation; Hospitalization is extended, needs additional oxygen; Hospitalization is extended, additional oxygen is not required; Discharged.Measure: Clinical status at the time of completion of participation in the study Time: through study completion, an average of 8 months